In Vitro Selection of an ATP-Binding TNA Aptamer

Zhang, Li; Chaput, John C.

doi:10.3390/molecules25184194

Cited by 18 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24) against both protein 139, 487-489 and small molecule targets. 490,491 Evolved polymerases also facilitate the selection of aptamers with other sugar modifications such as 2′-OMe groups 492 or bulkier functionalities appended at the 2′-position of the ribose. 493 In the latter approach, an engineered polymerase capable of efficient polymerization of 2′-modified nucleotides was used to construct libraries containing 2′-N 3 -modified cytosine nucleotides.…”

Section: Sugar-modified and Xna Containing Aptamersmentioning

confidence: 99%

Recent progress in non-native nucleic acid modifications

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Sugar-modified and Xna Containing Aptamersmentioning

confidence: 99%

Recent progress in non-native nucleic acid modifications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The work demonstrated that TNA could fold into tertiary structures with retained chemical functions, suggesting TNA as an RNA progenitor in the pre-RNA world. After that, various TNA aptamers with the capability of binding to small molecules and large proteins have been selected [ 178 , 179 , 180 , 181 , 182 , 183 ]. These TNA aptamers have remarkable thermal and biological stability.…”

Section: Chemically Modified Nucleic Acid Analoguesmentioning

confidence: 99%

Nucleic Acids and Their Analogues for Biomedical Applications

Wang

Chu

et al. 2022

Biosensors

View full text Add to dashboard Cite

Nucleic acids are emerging as powerful and functional biomaterials due to their molecular recognition ability, programmability, and ease of synthesis and chemical modification. Various types of nucleic acids have been used as gene regulation tools or therapeutic agents for the treatment of human diseases with genetic disorders. Nucleic acids can also be used to develop sensing platforms for detecting ions, small molecules, proteins, and cells. Their performance can be improved through integration with other organic or inorganic nanomaterials. To further enhance their biological properties, various chemically modified nucleic acid analogues can be generated by modifying their phosphodiester backbone, sugar moiety, nucleobase, or combined sites. Alternatively, using nucleic acids as building blocks for self-assembly of highly ordered nanostructures would enhance their biological stability and cellular uptake efficiency. In this review, we will focus on the development and biomedical applications of structural and functional natural nucleic acids, as well as the chemically modified nucleic acid analogues over the past ten years. The recent progress in the development of functional nanomaterials based on self-assembled DNA-based platforms for gene regulation, biosensing, drug delivery, and therapy will also be presented. We will then summarize with a discussion on the advanced development of nucleic acid research, highlight some of the challenges faced and propose suggestions for further improvement.

show abstract

“…This demonstrates the remarkable biostability of the TNA aptamer and the high level of selectivity in a large background of competing biomolecules. More recently, an ATP-binding aptamer composed entirely of TNA was obtained which showed high affinity to ATP and strong specificity against other naturally occurring ribonucleotide triphosphates [105]. TNA aptamer sequence can be minimized to a length that is compatible with chemical synthesis, which enables new applications that were previously not feasible for XNA aptamers due to the limited practical scale of enzymatic synthesis [104].…”

Section: Xeno-nucleic Acidsmentioning

confidence: 99%

Recent Progress and Opportunities for Nucleic Acid Aptamers

Byun

2021

Life

View full text Add to dashboard Cite

Coined three decades ago, the term aptamer and directed evolution have now reached their maturity. The concept that nucleic acid could modulate the activity of target protein as ligand emerged from basic science studies of viruses. Aptamers are short nucleic acid sequences capable of specific, high-affinity molecular binding, which allow for therapeutic and diagnostic applications. Compared to traditional antibodies, aptamers have several advantages, including small size, flexible structure, good biocompatibility, and low immunogenicity. In vitro selection method is used to isolate aptamers that are specific for a desired target from a randomized oligonucleotide library. The first aptamer drug, Macugen, was approved by FDA in 2004, which was accompanied by many studies and clinical investigations on various targets and diseases. Despite much promise, most aptamers have failed to meet the requisite safety and efficacy standards in human clinical trials. Amid these setbacks, the emergence of novel technologies and recent advances in aptamer and systematic evolution of ligands by exponential enrichment (SELEX) design are fueling hope in this field. The unique properties of aptamer are gaining renewed interest in an era of COVID-19. The binding performance of an aptamer and reproducibility are still the key issues in tackling current hurdles in clinical translation. A thorough analysis of the aptamer binding under varying conditions and the conformational dynamics is warranted. Here, the challenges and opportunities of aptamers are reviewed with recent progress.

show abstract

In Vitro Selection of an ATP-Binding TNA Aptamer

Cited by 18 publications

References 34 publications

Recent progress in non-native nucleic acid modifications

Recent progress in non-native nucleic acid modifications

Nucleic Acids and Their Analogues for Biomedical Applications

Recent Progress and Opportunities for Nucleic Acid Aptamers

Contact Info

Product

Resources

About